Based on our novel platform for treating autoimmune disease, we are developing TOL-3021, the first disease-modifying therapy for type 1 diabetes (T1D). We completed a Ph 2 study in T1D patients showing that, relative to placebo, TOL-3021 significantly improved C-peptide levels, an FDA-approvable biomarker of pancreatic insulin production and beta cell mass. As no disease-modifying drugs exist for T1D, the sales potential for TOL-3021 is large.